oa South African Family Practice - ONTARGET adds telmisartan to the gold standard list of anti-hypertensives : press release

Volume 50, Issue 2
  • ISSN : 2078-6190
  • E-ISSN: 2078-6204



At a recent local press conference at the Hilton Hotel, Johannesburg, the results of the landmark ONTARGET(R) trial were presented by Professor Pinky Sareli. This trial establishes telmisartan 80 mg as the only ARB clinically proven, to be as protective, but better tolerated than ramipril 10mg, in a broad high-risk cardiovascular population. From ONTARGET it may be concluded that telmisartan can prevent every 5th serious cardiovascular event. Prof Sareli further stated, categorically, that this is not an ARB class effect, but only applies to telmisartan.

Loading full text...

Full text loading...


Article metrics loading...


This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error